特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
969249

新型コロナウイルス感染症 (COVID-19) 診断の世界市場:国別の需要見通し、分子・血清診断 (アッセイ) の件数見通し (2021年12月まで)、最新の実績データ (2020年第1~第3四半期)

COVID-19 Global Diagnostic Demand Outlook by Country. Assay Volume Quarterly Outlook to December 2021 Separately for Molecular and Serology. Updated to Include Q1, Q2 & Q3 2020 Actuals Data

出版日: | 発行: Howe Sound Research | ページ情報: 英文 218 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=105.15円
新型コロナウイルス感染症 (COVID-19) 診断の世界市場:国別の需要見通し、分子・血清診断 (アッセイ) の件数見通し (2021年12月まで)、最新の実績データ (2020年第1~第3四半期)
出版日: 2020年11月02日
発行: Howe Sound Research
ページ情報: 英文 218 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートでは、新型コロナウイルス感染症 (COVID-19) 診断検査の需要見通しについて分析し、今後の感染拡大の速度について3通りのシナリオに基づいて、世界各国での診断検査の件数 (四半期ベース) を予測すると共に、検査手法別の詳細動向 (分子診断/血清診断ほか) や、直近の検査件数の実績値、検査手法の概要と活用状況、主要企業の対応状況、といった情報を取りまとめてお届けいたします。

目次

i. 新型コロナウイルス感染症 (COVID-19) 市場:戦略的状況分析

ii. 専門家向け提言

iii. 経営コンサルタント・投資顧問向け提言

第1章 イントロダクションと市場の定義

  • パンデミックとは何か?
  • 人獣共通感染症の役割
  • 市場の定義
  • 調査手法
  • パンデミックの歴史的展望
    • HIV/エイズ・パンデミック (2005年~2012年)
    • インフルエンザ・パンデミック (1968年)
    • アジア風邪 (1956年~1958年)
    • スペイン風邪 (1918年)
    • コレラ・パンデミック (1910年~1911年)
    • インフルエンザ・パンデミック (1889年~1890年)
    • 黒死病 (1346年~1353年)

第2章 パンデミックの概要

  • ウイルスとは何か?
  • コロナウイルス
    • 重症急性呼吸器症候群 (SARS)
    • 中東呼吸器症候群 (MERS)
    • 新型コロナウイルス感染症 (COVID-19) (SARS-CoV-2ウイルス)
  • パンデミックの診断
    • リスク管理:スパークアンドスプレッド
    • 診断技術:核酸ベース
    • 診断技術:イムノアッセイ
    • 市場投入までの時間と、準備の問題
    • 唾液直接検査

第3章 感染者/入院患者の予測:国別、四半期ベース、全シナリオ

  • シナリオの概要
    • WHO:世界健康安全保障指数 (GHIS)
    • 感染拡大の進行状況:予測手法
  • シナリオ1:最善のケース
  • シナリオ2:予想されるケース
  • シナリオ3:最悪のケース

第4章 診断企業のプロファイル

  • 1drop
  • Abbott Diagnostics
  • Accelerate Diagnostics
  • Ador Diagnostics
  • Advanced Biological Laboratories
  • Akkoni Biosystems
  • Altona Diagnostics
  • Alveo Technologies
  • Applied BioCode
  • Applied DNA Sciences
  • Anatolia Geneworks
  • Assurance Scientific Laboratories
  • Aus Diagnostics
  • Autobio Diagnostics
  • BD Diagnostics
  • BGI Genomics Co. Ltd
  • Biocartis
  • Biodesix
  • BioFire Diagnostics
  • Biolidics
  • bioMérieux
  • Bioneer
  • Bio-Rad Laboratories
  • BioReference Laboratories
  • Bosch Healthcare Solutions GmbH
  • Cepheid
  • Cerstest Biotec
  • Chembio Diagnostics
  • Color Genomics
  • Credo Diagnostics Biomedical
  • Curetis
  • Diagenode Diagnostics
  • Diascopic
  • Diasorin
  • Enzo Life Sciences, Inc.
  • Exact Sciences
  • Expedeon
  • Fulgent Genetics
  • Fusion Genomics.
  • Genedrive
  • GenePOC Diagnostics
  • Genetic Signatures
  • Genetron
  • GenMark Dx
  • Gold Standard Diagnostics
  • Hologic
  • Immunexpress
  • Inflammatix
  • Invetech
  • Janssen Diagnostics
  • Karius
  • Laboratory Corporation of America
  • Lexagene
  • Luminex
  • Mayo Clinic Laboratories
  • Mbio Diagnostics
  • Meridian Bioscience
  • Mesa Biotech
  • Mobidiag
  • Nanomix
  • Novacyt
  • Orig3n
  • Ortho Clinical Diagnostics
  • Oxford Nanopore
  • Panagene
  • PerkinElmer
  • Primerdesign
  • Prominex
  • Qiagen (Statdx)
  • Quantumdx
  • Quest Diagnostics
  • Quidel
  • Randox Laboratories
  • Roche Molecular Diagnostics
  • Saw Diagnostics
  • SD Biosensor
  • Seegene
  • Sensovation
  • Siemens Healthineers (Fast Track Diagnostics)
  • SkylineDx
  • Sona Nanotech
  • T2 Biosystems
  • Thermo Fisher
  • Veredus Labs
  • Vircell
  • YD Diagnostics
  • Zhejiang Orient Gene Biotech

第6章 診断用 (DX) 医療システムの需要見通し

  • 医療システム需要、国別:最善のケース
  • 医療システム需要、国別:予想されるケース
  • 医療システム需要、国別:最悪のケース

第7章 分子・血清診断の需要見通し

  • 分子・血清診断需要、国別:最善のケース
  • 分子・血清診断需要、国別:予想されるケース
  • 分子・血清診断需要、国別:最悪のケース
図表

Table of Tables

  • Table 1 Who List of Potential Pandemic Pathogens
  • Table 2 Characteristics of Coronavirus Pandemic Infections
  • Table 3 COVID-19 Symptoms
  • Table 4 The Three Scenarios
  • Table 5 Test Consumption Outlook Based on Mid July Daily Run Rate - Relative Percentages per quarter
  • Table 6 Scenario 1 Assumptions
  • Table 7 Scenario 2 Assumptions
  • Table 8 Scenario 3 Assumptions
  • Table 9 - Healthcare Dx Total Demand by Country - Best Case
  • Table 10 - Healthcare Dx Total Met Demand by Country - Expected Case
  • Table 11 - Healthcare Dx Total Demand by Country - Worst Case
  • Table 12 - Molecular Dx Total Demand by Country - Best Case
  • Table 13 - Molecular Dx Total Demand by Country - Expected Case
  • Table 14 - Serology Dx Total Demand by Country - Expected Case
  • Table 15 - Molecular Dx Total Demand by Country - Worst Case
  • Table 16 - Serology Dx Total Demand by Country - Worst Case

Table of Figures

  • Figure 1 Global Distribution Pandemic Preparedness
  • Figure 2 Global Pandemic Pathogen Status
  • Figure 3 Estimated Economic Impact of Viral Pandemic by Region
  • Figure 4 Historical Pandemics Infographic
  • Figure 5 Antigenic Drift Creates a new Strain of Virus
  • Figure 6 Structure of Coronaviruses
  • Figure 7 1918 Flu - 2 Infection Curves
  • Figure 8 Global Healthcare Diagnostics Demand by Quarter - Best Case
  • Figure 9 Global Healthcare Diagnostics Demand by Quarter - Expected Case
  • Figure 10 Global Healthcare Diagnostics Demand by Quarter - Worst Case
  • Figure 11 Global Healthcare Diagnostics Molecular Demand by Quarter - Best Case
  • Figure 12 Global Healthcare Diagnostics Serology Demand by Quarter - Best Case
  • Figure 13 Global Healthcare Diagnostics Molecular Demand by Quarter - Expected Case
  • Figure 14 Global Healthcare Diagnostics Total Demand by Quarter - Expected Case
  • Figure 15 Global Healthcare Diagnostics Molecular Demand by Quarter - Best Case
  • Figure 16 Global Healthcare Diagnostics Serology Demand by Quarter - Worst Case.......... 217
目次

OVERVIEW:

Can diagnostics stop an epidemic? Rapid diagnostics is key to epidemic management. But the demand is staggering. Will it stagger the diagnostics industry? This report looks at the assay volume demands by country looking out 5 quarters to the end of 2021. We look at 3 scenarios for pandemic progression and explore diagnostics demand in each scenario. A breakout of Molecular and Serology is also included. As always, our analysts are available to breakout separate numbers to meet your needs and work with your assumptions.

Our forecasts are based on the WHO Health Security Index with specific assumptions about the effectiveness of distancing measures and the impact of health system overload on different countries. These create varying timelines of demand.

All report data is available in Excel format on request.

Make projections with confidence using the latest data.

ABOUT THE LEAD AUTHOR:

Mr. Greg Powell, B.SC., M.B.A is the President of Howe Sound Research. He is an experienced business and clinical professional. He is co-author of the paper "The Radioimmunoassay of Angiotensinogen by Antibody Trapping." He has worked in laboratory testing and management for over 20 years. Mr. Powell's education includes:

  • B.Sc. (Chemistry) University of BC
  • M.B.A. (Finance and Policy) University of BC
  • Market Research Seminar - Burke Institute
  • Finance for Senior Executives - Harvard Business School

Table of Contents

i. COVID-19. Strategic Situation Analysis

  • ii. COVID-19. Guidance for Executives
  • iii. COVID-19. Guidance for Management Consultants and Investment Advisors

1. Introduction and Market Definition

  • 1.1 What are Pandemics?
  • 1.2 The Role of Zoonosis
  • 1.3 Market Definition
    • 1.3.1 Assay Volumes.
    • 1.3.2 Healthcare Systems Demand
    • 1.3.3 Molecular & Serology
  • 1.4 Methodology
    • 1.4.1 Authors
    • 1.4.2 Sources
  • 1.5 Historical Perspective on Pandemics
    • 1.5.1 HIV/AIDS PANDEMIC 2005-2012
    • 1.5.2 FLU PANDEMIC 1968
    • 1.5.3 ASIAN FLU 1956-1958
    • 1.5.4 SPANISH FLU 1918
    • 1.5.5 SIXTH CHOLERA PANDEMIC 1910-1911
    • 1.5.6 FLU PANDEMIC 1889-1890
    • 1.5.7 THE BLACK DEATH 1346-1353

2. The Pandemic Overview

  • 2.1 What is a Virus?
    • 2.1.1 Is a Virus Alive?
    • 2.1.2 Viral Structure
    • 2.1.3 The Viral Genome
    • 2.1.4 Viral Mutation
  • 2.2 The Coronavirus
    • 2.2.1 Severe acute respiratory syndrome (SARS)
    • 2.2.2 Middle East respiratory syndrome (MERS)
    • 2.2.3 COVID-19. The SARS CoV 2 Virus
      • 2.2.3.1 Signs and symptoms
      • 2.2.3.2 Transmission
      • 2.2.3.3 Diagnosis
      • 2.2.3.4 Prevention
      • 2.2.3.5 Management
      • 2.2.3.6 Prognosis
      • 2.2.3.7 A Note on Global Statistics Reporting
  • 2.3 Pandemic Diagnostics
    • 2.3.1 Risk Management - Spark and Spread
    • 2.3.2 Dx Technology - Nucleic Acid Based
    • 2.3.3 Dx Technology - Immunoassay
    • 2.3.4 Time to Market and Preparedness Issues
    • 2.3.5 Saliva Direct Test
      • 2.3.5.1 Research Abstract
      • 2.3.5.2 FDA Statement on Saliva Direct Test
      • 2.3.5.3 Impact of Saliva Direct on Forecasts and Cannibalization

3. Infection/Hospitalization Projections by Country by Quarter. All Case Secenarios

  • 3.1 Scenarios Overview
    • 3.1.1 WHO Global Health Security Index
    • 3.1.2 Pandemic Progression Outlook Methodology
  • 3.2 Scenario 1. Best Case
  • 3.3 Scenario 2. Expected Case
  • 3.4 Scenario 3. Worst Case

4. Diagnostic Company Profiles

  • 1drop
  • Abbott Diagnostics
  • Accelerate Diagnostics
  • Ador Diagnostics
  • Advanced Biological Laboratories
  • Akkoni Biosystems
  • Altona Diagnostics
  • Alveo Technologies
  • Applied BioCode
  • Applied DNA Sciences
  • Anatolia Geneworks
  • Assurance Scientific Laboratories
  • Aus Diagnostics
  • Autobio Diagnostics
  • BD Diagnostics
  • BGI Genomics Co. Ltd
  • Biocartis
  • Biodesix
  • BioFire Diagnostics
  • Biolidics
  • bioMérieux
  • Bioneer
  • Bio-Rad Laboratories
  • BioReference Laboratories
  • Bosch Healthcare Solutions GmbH
  • Cepheid
  • Cerstest Biotec
  • Chembio Diagnostics
  • Color Genomics
  • Credo Diagnostics Biomedical
  • Curetis
  • Diagenode Diagnostics
  • Diascopic
  • Diasorin
  • Enzo Life Sciences, Inc.
  • Exact Sciences
  • Expedeon
  • Fulgent Genetics
  • Fusion Genomics.
  • Genedrive
  • GenePOC Diagnostics
  • Genetic Signatures
  • Genetron
  • GenMark Dx
  • Gold Standard Diagnostics
  • Hologic
  • Immunexpress
  • Inflammatix
  • Invetech
  • Janssen Diagnostics
  • Karius
  • Laboratory Corporation of America
  • Lexagene
  • Luminex
  • Mayo Clinic Laboratories
  • Mbio Diagnostics
  • Meridian Bioscience
  • Mesa Biotech
  • Mobidiag
  • Nanomix
  • Novacyt
  • Orig3n
  • Ortho Clinical Diagnostics
  • Oxford Nanopore
  • Panagene
  • PerkinElmer
  • Primerdesign
  • Prominex
  • Qiagen (Statdx)
  • Quantumdx
  • Quest Diagnostics
  • Quidel
  • Randox Laboratories
  • Roche Molecular Diagnostics
  • Saw Diagnostics
  • SD Biosensor
  • Seegene
  • Sensovation
  • Siemens Healthineers (Fast Track Diagnostics)
  • SkylineDx
  • Sona Nanotech
  • T2 Biosystems
  • Thermo Fisher
  • Veredus Labs
  • Vircell
  • YD Diagnostics
  • Zhejiang Orient Gene Biotech

6. Healthcare Systems Dx Demand Outlook

  • 6.1 Healthcare System Demand by Country - Best Case
    • 6.1.1 Table - Healthcare Dx Total Demand by Country - Best Case
    • 6.1.3 Chart - Global Healthcare Dx Total Demand by Quarter - Best Case
  • 6.2 Healthcare System Demand by Country - Expected Case
    • 6.2.1 Table - Healthcare Dx Total Demand by Country - Expected Case
    • 6.2.3 Chart - Global Healthcare Dx Total Demand by Quarter - Expected Case
  • 6.3 Healthcare System Demand by Country - Worst Case
    • 6.3.1 Table - Healthcare Dx Total Demand by Country - Worst Case
    • 6.3.3 Chart - Global Healthcare Dx Total Demand by Quarter - Worst Case

7. Molecular/Serology Dx Demand Outlook

  • 7.1 Molecular/Serology Demand by Country - Best Case
    • 7.1.1 Table - Molecular Dx Total Demand by Country - Best Case
    • 7.1.2 Table - Serology Dx Total Demand by Country - Best Case
    • 7.1.3 Chart - Global Molecular Dx Total Demand by Quarter - Best Case
    • 7.1.4 Chart - Global Serology Dx Total Demand by Quarter - Best Case
  • 7.2 Molecular/Serology Demand by Country - Expected Case
    • 7.2.1 Table - Molecular Dx Total Demand by Country - Expected Case
    • 7.2.2 Table - Serology Dx Total Demand by Country - Expected Case
    • 7.2.3 Chart - Global Molecular Dx Total Demand by Quarter - Expected Case
    • 7.2.4 Chart - Global Serology Dx Total Demand by Quarter - Expected Case
  • 7.3 Molecular/Serology Demand by Country - Worst Case
    • 7.3.1 Table - Molecular Dx Total Demand by Country - Worst Case
    • 7.3.2 Table - Serology Dx Total Demand by Country - Worst Case
    • 7.3.3 Chart - Global Molecular Dx Total Demand by Quarter - Worst Case
    • 7.3.4 Chart - Global Serology Dx Total Demand by Quarter - Worst Case
株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.